Nuvation Bio's Taletrectinib Clears Key UK Regulatory Milestone for ROS1+ Lung Cancer
Nuvation Bio, a global oncology company dedicated to addressing some of the most challenging areas in cancer care, has announced that the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for review a Marketing Authorisation Application (MAA) submitted by its partner, Eisai Co., Ltd., for taletrectinib as a treatment for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).
The submission was made under the International Recognition Procedure, a pathway designed to accelerate patient access to medicines by considering approvals from trusted international regulatory authorities. The MHRA will now conduct its assessment to determine whether the therapy should be authorized in the United Kingdom.
In January 2026, Nuvation Bio and Eisai entered into an exclusive licensing and collaboration agreement covering Europe and several territories outside the United States, China, and Japan, with the goal of expanding global access to taletrectinib. The oral therapy, marketed as IBTROZI® in the U.S. and Japan, is intended for patients with advanced ROS1+ NSCLC. The European Medicines Agency accepted the drug's MAA for review in March 2026, and additional regulatory submissions are planned in Canada and other regions included within Eisai's licensed territories.
Approximately 50,200 new lung cancer cases are diagnosed annually in the United Kingdom. Non-small cell lung cancer accounts for roughly 80% to 85% of these cases, with an estimated 2% of patients carrying the ROS1-positive mutation.
The regulatory filing is supported by findings from the pivotal Phase 2 TRUST-I and TRUST-II clinical trials, which evaluated taletrectinib in patients worldwide. Combined analyses from the TRUST program were first published in the Journal of Clinical Oncology in April 2025. Updated data, reflecting extended patient follow-up, were presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, further strengthening the treatment's observed efficacy and safety profile. Additional findings from the TRUST-I study were also published in the Journal of Clinical Oncology during the same month.
David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, welcomed the advancement of taletrectinib into the U.K. regulatory review process following recent progress in Europe. He noted that the therapy has already demonstrated meaningful benefits for patients in the United States, China, and Japan, and emphasized that the latest milestone represents another important step toward broadening global access to the treatment.
In June 2025, the U.S. Food and Drug Administration granted full approval to taletrectinib for patients with locally advanced or metastatic ROS1+ NSCLC across multiple lines of therapy, following a Priority Review process and the awarding of two Breakthrough Therapy designations. The treatment has also been approved in Japan, where it is marketed by Nippon Kayaku, and in China, where Innovent Biologics markets it under the brand name DOVBLERON.
Eisai's licensed territories for taletrectinib include Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam, and India.
The submission was made under the International Recognition Procedure, a pathway designed to accelerate patient access to medicines by considering approvals from trusted international regulatory authorities. The MHRA will now conduct its assessment to determine whether the therapy should be authorized in the United Kingdom.
In January 2026, Nuvation Bio and Eisai entered into an exclusive licensing and collaboration agreement covering Europe and several territories outside the United States, China, and Japan, with the goal of expanding global access to taletrectinib. The oral therapy, marketed as IBTROZI® in the U.S. and Japan, is intended for patients with advanced ROS1+ NSCLC. The European Medicines Agency accepted the drug's MAA for review in March 2026, and additional regulatory submissions are planned in Canada and other regions included within Eisai's licensed territories.
Approximately 50,200 new lung cancer cases are diagnosed annually in the United Kingdom. Non-small cell lung cancer accounts for roughly 80% to 85% of these cases, with an estimated 2% of patients carrying the ROS1-positive mutation.
The regulatory filing is supported by findings from the pivotal Phase 2 TRUST-I and TRUST-II clinical trials, which evaluated taletrectinib in patients worldwide. Combined analyses from the TRUST program were first published in the Journal of Clinical Oncology in April 2025. Updated data, reflecting extended patient follow-up, were presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, further strengthening the treatment's observed efficacy and safety profile. Additional findings from the TRUST-I study were also published in the Journal of Clinical Oncology during the same month.
David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, welcomed the advancement of taletrectinib into the U.K. regulatory review process following recent progress in Europe. He noted that the therapy has already demonstrated meaningful benefits for patients in the United States, China, and Japan, and emphasized that the latest milestone represents another important step toward broadening global access to the treatment.
In June 2025, the U.S. Food and Drug Administration granted full approval to taletrectinib for patients with locally advanced or metastatic ROS1+ NSCLC across multiple lines of therapy, following a Priority Review process and the awarding of two Breakthrough Therapy designations. The treatment has also been approved in Japan, where it is marketed by Nippon Kayaku, and in China, where Innovent Biologics markets it under the brand name DOVBLERON.
Eisai's licensed territories for taletrectinib include Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam, and India.
Companies